{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T07:53:02Z","timestamp":1770882782681,"version":"3.50.1"},"reference-count":46,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1016\/j.mcna.2012.01.009","type":"journal-article","created":{"date-parts":[[2012,3,5]],"date-time":"2012-03-05T22:21:37Z","timestamp":1330986097000},"page":"13-26","source":"Crossref","is-referenced-by-count":65,"title":["LDL Cholesterol: The Lower the Better"],"prefix":"10.1016","volume":"96","author":[{"given":"Seth S.","family":"Martin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger S.","family":"Blumenthal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mcna.2012.01.009_bib1","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.mcna.2012.01.009_bib2","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.mcna.2012.01.009_bib3","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1161\/CIRCULATIONAHA.108.191259","article-title":"Heart disease and stroke statistics\u20142009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee","volume":"119","author":"Lloyd-Jones","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.mcna.2012.01.009_bib4","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.1984.03340270029025","article-title":"The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease","volume":"251","year":"1984","journal-title":"JAMA"},{"key":"10.1016\/j.mcna.2012.01.009_bib5","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jama.1984.03340270043026","article-title":"The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering","volume":"251","year":"1984","journal-title":"JAMA"},{"key":"10.1016\/j.mcna.2012.01.009_bib6","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.mcna.2012.01.009_bib7","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1016\/j.jacc.2004.03.046","article-title":"Optimal low-density lipoprotein is 50 to 70 mg\/dL: lower is better and physiologically normal","volume":"43","author":"O\u2019Keefe","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.mcna.2012.01.009_bib8","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1172\/JCI115499","article-title":"Role of oxidized low density lipoprotein in atherogenesis","volume":"88","author":"Witztum","year":"1991","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.mcna.2012.01.009_bib9","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1001\/jama.290.7.891","article-title":"Major risk factors as antecedents of fatal and nonfatal coronary heart disease events","volume":"290","author":"Greenland","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.mcna.2012.01.009_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-74-1-1","article-title":"Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study","volume":"74","author":"Kannel","year":"1971","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.mcna.2012.01.009_bib11","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/archinte.1992.00400130082009","article-title":"Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group","volume":"152","author":"Neaton","year":"1992","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.mcna.2012.01.009_bib12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0749-3797(19)30122-9","article-title":"The prediction of midlife coronary heart disease and hypertension in young adults: the Johns Hopkins multiple risk equations","volume":"6","author":"Pearson","year":"1990","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.mcna.2012.01.009_bib13","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1056\/NEJM199806043382302","article-title":"Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study","volume":"338","author":"Berenson","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2012.01.009_bib14","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1001\/jama.2009.1672","article-title":"Trends in high levels of low-density lipoprotein cholesterol in the United States, 1999-2006","volume":"302","author":"Kuklina","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.mcna.2012.01.009_bib15","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.mcna.2012.01.009_bib16","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0140-6736(95)90926-5","article-title":"Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S)","volume":"345","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.mcna.2012.01.009_bib17","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group","volume":"333","author":"Shepherd","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2012.01.009_bib18","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators","volume":"335","author":"Sacks","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2012.01.009_bib19","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group","volume":"339","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2012.01.009_bib20","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.mcna.2012.01.009_bib21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.mcna.2012.01.009_bib22","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2012.01.009_bib23","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2012.01.009_bib24","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","article-title":"Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial","volume":"292","author":"de Lemos","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.mcna.2012.01.009_bib25","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","article-title":"High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial","volume":"294","author":"Pedersen","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.mcna.2012.01.009_bib26","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2012.01.009_bib27","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","article-title":"Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial","volume":"291","author":"Nissen","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.mcna.2012.01.009_bib28","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1001\/jama.295.13.jpc60002","article-title":"Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial","volume":"295","author":"Nissen","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.mcna.2012.01.009_bib29","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.297.12.1344","article-title":"Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial","volume":"297","author":"Crouse","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.mcna.2012.01.009_bib30","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1110874","article-title":"Effect of two intensive statin regimens on progression of coronary disease","volume":"365","author":"Nicholls","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2012.01.009_bib31","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/BF02938395","article-title":"Residual risk in statin-treated patients: future therapeutic options","volume":"9","author":"Campbell","year":"2007","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.mcna.2012.01.009_bib32","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen year mortality in coronary drug project patients: long-term benefit with niacin","volume":"8","author":"Canner","year":"1986","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.mcna.2012.01.009_bib33","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2012.01.009_bib34","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1185\/03007995.2011.571239","article-title":"Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis","volume":"27","author":"Mikhailidis","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.mcna.2012.01.009_bib35","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1056\/NEJMoa0800742","article-title":"Simvastatin with or without ezetimibe in familial hypercholesterolemia","volume":"358","author":"Kastelein","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2012.01.009_bib36","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa0907569","article-title":"Extended-release niacin or ezetimibe and carotid intima-media thickness","volume":"361","author":"Taylor","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2012.01.009_bib37","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.mcna.2012.01.009_bib38","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1161\/CIRCULATIONAHA.106.624890","article-title":"Risks associated with statin therapy: a systematic overview of randomized clinical trials","volume":"114","author":"Kashani","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.mcna.2012.01.009_bib39","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.clinthera.2007.08.022","article-title":"Does statin therapy initiation increase the risk for myopathy? an observational study of 32,225 diabetic and nondiabetic patients","volume":"29","author":"Nichols","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.mcna.2012.01.009_bib40","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/S0140-6736(07)60716-8","article-title":"The safety of statins in clinical practice","volume":"370","author":"Armitage","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.mcna.2012.01.009_bib41","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/S0140-6736(10)61272-X","article-title":"Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis","volume":"376","author":"Athyros","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.mcna.2012.01.009_bib42","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.mcna.2012.01.009_bib43","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jama.295.1.74","article-title":"Statins and cancer risk: a meta-analysis","volume":"295","author":"Dale","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.mcna.2012.01.009_bib44","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S0002-9343(00)00353-3","article-title":"Effects of lovastatin on cognitive function and psychological well-being","volume":"108","author":"Muldoon","year":"2000","journal-title":"Am J Med"},{"key":"10.1016\/j.mcna.2012.01.009_bib45","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.jacc.2010.09.082","volume":"57","author":"Hsia","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.mcna.2012.01.009_bib46","doi-asserted-by":"crossref","first-page":"89C","DOI":"10.1016\/j.amjcard.2006.02.030","article-title":"Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force","volume":"97","author":"McKenney","year":"2006","journal-title":"Am J Cardiol"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712512000107?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712512000107?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T00:04:04Z","timestamp":1561421044000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712512000107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S0025712512000107"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2012.01.009","relation":{},"ISSN":["0025-7125"],"issn-type":[{"value":"0025-7125","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}